Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.52 |
| ▸ | NPY1R | P25929 | 8/20 | 0.52 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.52 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | SCTR | P47872 | 1/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.42 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710584 | 0.98 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL6710592 | 0.98 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29659741 | 0.93 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29965839 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30645267 | 0.93 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL30140911 | 0.92 | GLP1R (0.51) | GLP1RSCTRVIPR2VIPR1 | |
| SCHEMBL29948315 | 0.92 | C5AR1 (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29904562 | 0.92 | C5AR1 (0.55) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30490412 | 0.91 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5RAPLNR | |
| SCHEMBL31529444 | 0.91 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139003-A1 | PEPTIDE WITH ACTIVITY OF PROMOTING HAIR GROWTH AND INHIBITING HAIR LOSS AND USE THEREOF | CAREGEN CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| EP-4603499-A1 | PEPTIDE WITH ACTIVITY OF PROMOTING HAIR GROWTH AND INHIBITING HAIR LOSS AND USE THEREOF | Caregen Co., Ltd. (KR) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024080399-A1 | PEPTIDE WITH ACTIVITY OF PROMOTING HAIR GROWTH AND INHIBITING HAIR LOSS AND USE THEREOF | (주)케어젠 | 2024-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139003-A1 | PEPTIDE WITH ACTIVITY OF PROMOTING HAIR GROWTH AND INHIBITING HAIR LOSS AND USE THEREOF | DKK1, DKC1, NR5A1 | NPY4R 342/4885NPY1R 326/4885NPY2R 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.